Proteomics International Laboratories Ltd. · ASX:PIQ
Proteomics International Laboratories — Investor Presentation (March 2024)
28 slides from Proteomics International Laboratories's investor presentation, Mar 28, 2024
Slide 1: ASX Release: Investor Presentation
ASX Release 28 March 2024 ASX code: PIQ Investor Presentation Proteomics International Laboratories Ltd (Proteomics International; the Company; ASX: PIQ) is pleased to release a copy of the presentation to be provided by Dr Richard Lipscombe to Jefferies Institutional Clients on 28 March 2024. Autho
Slide 2: Proteomics International Investor Presentation
ASX: PIQ Proteomics International LABORATORIES LTD Investor Presentation 28 March 2024 Dr. Richard Lipscombe Managing Director 1
Slide 3: Disclaimer
Disclaimer ASX: PIQ This Presentation is provided by Proteomics International Laboratories Ltd (Proteomics International, Proteomics, the Company, ASX: PIQ). You should not rely upon anything in this presentation and/or any information obtained from the Company, its Directors or their associates in
Slide 4: Proteomics International Laboratories Ltd
Proteomics International Laboratories Ltd ASX: PIQ A medical technology company at the forefront of predictive diagnostics and precision medicine Three key focus tests driven by a proprietary platform technology: • Proven prognostic test for predicting the onset of diabetic kidney disease • Being co
Slide 5: Corporate Overview
Corporate Overview ASX: PIQ Corporate Snapshot Financial and Corporate ASX code PIQ Market Capitalisation A$136m • Top 40 Shareholders hold 53% Cash (31 Dec 2023 + Placement Proceeds) ~A$11m Share Price (26 Mar 2024) A$1.04 • Directors are highly aligned with shareholders holding 14% Shares on issue
Slide 6: Promarker – Platform Technology
Promarker – Platform Technology ASX: PIQ PromarkerTM is a platform technology that can identify unique protein biomarkers ‘fingerprints’ The platform identifies and links the unique protein biomarkers to specific diseases, enabling Proteomics International to create novel diagnostic tests 5
Slide 7: Promarker D
Promarker D PROACTIVELY CHANGING RENAL HEALTHCARE Asimple blood test for predicting diabetic kidney disease
Slide 8: Problem and Solution – Diabetic Kidney Disease
Problem and Solution – Diabetic Kidney Disease ASX: PIQ Current standard-of-care diagnostics • Existing tests (known as eGFR and ACR) can only detect chronic kidney disease once it is already present • Current standard-of-care tests cannot predict the onset Roadblock of diabetic kidney disease The P
Slide 9: PromarkerD Global Rollout: Key Highlights
PromarkerD Global Rollout: Key Highlights ASX: PIQ Intellectual Property Patents granted in all major jurisdictions - PromarkerD Patent family & Trademark covers 72% of world’s diabetics CE Mark (EU) registration received for the PromarkerD Immunoassay IVD Regulatory Secured ISO 13485 certification
Slide 10: United States: Commercialisation in Progress
United States: Commercialisation in Progress ASX: PIQ Sonic Healthcare USA has the exclusive licence to commercialise PromarkerD in the world’s largest healthcare market Over 7,000 Employees Over 300 Sales reps Over 400 pathologists Services over 20 million patients Marketing, Sample collection, Rep
Slide 11: Reimbursement in the US
Reimbursement in the US ASX: PIQ Proteomics International has worked with its partner Sonic Healthcare USA to achieve reimbursement in the US CMS is the federal agency Medicare and Medicaid CMS is responsible for CMS has assigned a in the United States that collectively responsible for providing hea
Slide 12: Target Markets: PromarkerD
Target Markets: PromarkerD ASX: PIQ Proteomics International is showcasing PromarkerD with KOL’s at major conferences globally • PromarkerD is CE Mark registered in Europe • Germany, France and Spain are initial target markets Next Steps Germany, France, • Options to commercialise PromarkerD via: •
Slide 13: Pipeline of Precision Diagnostics
Pipeline of Precision Diagnostics ASX: PIQ Platform technology drives deep pipeline of novel diagnostic tests Further global potential in new markets • Promarker platform develops novel intellectual property • Targeting new diagnostic tests in areas of significant unmet need • Enormous markets and r
Slide 14: Dx Pipeline: Endometriosis
Dx Pipeline: Endometriosis ASX: PIQ Potential world-first blood test ‘PromarkerEndo’ in late-stage development Impact of Endometriosis • Endometriosis is a common and painful disease where uterus tissue grows into other organs • Currently diagnosis takes an average of 7.5 years and requires invasive
Slide 15: Dx Pipeline: Esophageal Cancer
Dx Pipeline: Esophageal Cancer ASX: PIQ Potential world-first blood test ‘PromarkerEso’ in late-stage development Impact of Esophageal Cancer • 1 in 20 cancer deaths worldwide due to esophageal cancer - 5 year survival rate < 20% • Currently diagnosis requires a specialist endoscopy procedure; treat
Slide 16: Dx Pipeline: Oxidative Stress
Dx Pipeline: Oxidative Stress ASX: PIQ Potential world-first blood test in late-stage development What is Oxidative Stress? Broad applications of OxiDx technology: • Oxidative stress occurs when the body’s ➢ Athletic monitoring tool for competition preparedness: antioxidant defences are overwhelmed
Slide 17: Timeline, Milestones & Catalysts
Timeline, Milestones & Catalysts ASX: PIQ CY23 & CY24 Key Milestones Achieved CY24 Share Price Catalysts 1 Jan 2024 25 Mar 2024 ❖ Generate sales revenue for 10 May 2023 PromarkerD Agreement with PromarkerD in the USA Sonic Healthcare USA reimbursement pricing Oxford University for Licence Agreement
Slide 18: PIQ – an exceptional global opportunity
PIQ – an exceptional global opportunity ASX: PIQ Investment Highlights ➢ Disruptive, cutting-edge technology & proven in-house diagnostics platform ➢ PromarkerD test de-risked, patented, revenue ready with high margins ➢ PromarkerD test manufactured in easy-to-use, scalable, low-cost format ➢ Partne
Slide 19: Contact
Contact ASX: PIQ Dr Richard Lipscombe Dirk van Dissel Managing Director Investor Relations & Corporate Advisor T: +61 8 9389 1992 Candour Advisory E: enquiries@proteomicsinternational.com T: +61 408 326 367 www.proteomicsinternational.com E: dirk@candouradvisory.com.au Kyle Moss Corporate Advisor Eu
Slide 20: Supplemental
Supplemental ASX: PIQ 19
Slide 21: Board of Directors
Board of Directors ASX: PIQ Neville Gardiner BBus (Accounting and Business Law) (Curtin), Non-Executive Chair Seasoned finance professional with over 30 years’ experience providing corporate advice to Boards of public and private companies. South & He was Co-Founder and MD of Torridon Partners, an i
Slide 22: PromarkerD: World Class Advisory Board
PromarkerD: World Class Advisory Board ASX: PIQ Proteomics International is supported by an international, highly acclaimed advisory board Professor Tim Davis MedSc, MB, W.Aust., DPhil Oxf., Associate Professor Michael Shanik MD, FACP, FACE FRACP, MRCP (UK) – Australia – United States Consultant phy
Slide 23: PromarkerD - Patented in all Major Markets
PromarkerD - Patented in all Major Markets ASX: PIQ Diabetic Kidney Disease is becoming one of the largest burdens on healthcare systems globally Patent family & Trademark covers 72% of world’s diabetics1 45% Country Patent/Application No Patent Status No. Diabetics1 undiagnosed Australia 2011305050
Slide 24: PromarkerD – Simple Integration & Use
PromarkerD – Simple Integration & Use ASX: PIQ Blood sample drawn Biomarkers analysed Results generated by Results and intervention plan PromarkerD Hub software delivered Sample is drawn at clinic or Laboratory uses a standard Cloud based algorithm, the Clinician delivers results to patient patholog
Slide 25: PromarkerD – Results & Intervention
PromarkerD – Results & Intervention ASX: PIQ How PromarkerD results are delivered LOW RISK MODERATE RISK HIGH RISK RISK SCORE % 0 10 20 100 Prognostic 16% indicates a moderate risk of decline in kidney function* Risk Score Intervention Testing Regimen Low Risk • Standard diabetes management Test Ann
Slide 26: PromarkerD in the Clinic
PromarkerD in the Clinic ASX: PIQ Peer Reviewed Physician Support Outperforms Standard of Care PromarkerD tested on over 5,000 Survey of 400 Endocrinologists & • 857 community based patients tested for patients in 4-year clinical studies Primary Care Physicians (US based) existing DKD at baseline: 4
Slide 27: PromarkerD: Precision Medicine
PromarkerD: Precision Medicine ASX: PIQ The Need The Treatments The Utility There is a significant and growing need for Patients identified as high-risk of DKD by Complementary diagnostic intervention for diabetic kidney disease (DKD) PromarkerD now have multiple preventative Early diagnosis of DKD
Slide 28: PromarkerD: Key Publications
PromarkerD: Key Publications ASX: PIQ PromarkerD Demonstrates Benefit of Peters KE, et al. Canagliflozin Attenuates PromarkerD Diabetic Kidney Disease Risk Prediction Score. J Clinical Early Treatment with SGLT2-inhibitors Medicine. 2023. Fusfeld L, et al. Evaluation of the clinical utility of the P
Proteomics International Laboratories — Investor Presentation (March 2024) on 6ix